

United States Patent and Trademark Office
- Sales Receipt -

05/05/2006 DWILLIA4 00000001 201430 10539534

01 FC:1202 100.00 DA

PATENT APPLICATION FEE DETERMINATION RECORD
Effective December 8, 2004

Application or Docket Number

10/539534

CLAIMS AS FILED - PART I

National Stage Processing
Patent Specialist
(703) 305-9221

Washington, D.C.

U.S. NATIONAL STAGE FEES			
BASIC FEE		SMALL ENT. = \$ 150	LARGE ENT. = \$ 300
EXAMINATION FEE		Satisfies PCT Article 33(1)- (4) = \$ 50 / \$ 100	All other situations = \$ 100 / \$ 200
SEARCH FEE		U.S. or ISA = \$ 50 / \$ 100 ALL other countries = \$ 200 / \$ 400	All other situations = \$ 250 / \$ 500
FEE FOR EXTRA SPEC. PGS.		minus 100 =	/ 50 =
TOTAL CHARGEABLE CLAIMS	35	minus 20 =	- 15
INDEPENDENT CLAIMS	3	minus 3 =	
MULTIPLE DEPENDENT CLAIM PRESENT			<input checked="" type="checkbox"/>

* If the difference in column 1 is less than zero, enter "0" in column 2

SMALL ENTITY
TYPE

RATE	FEES
BASIC FEE	
EXAM. FEE	
SEARCH FEE	
X \$ 125 =	
X \$ 25 =	
X \$ 100 =	
+ \$ 180 =	
TOTAL	

Washington, D.C.
National Stage Processing
Patent Specialist
(703) 305-9221

OTHER THAN
SMALL ENTITY

RATE	FEES
BASIC FEE	300
EXAM. FEE	200
SEARCH FEE	400
X \$ 250 =	
X \$ 50 =	750
X \$ 200 =	
+ \$ 360 =	300
TOTAL	

CLAIMS AS AMENDED - PART II

(Column 1) (Column 2) (Column 3)

AMENDMENT A	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	SMALL ENTITY		OTHER THAN SMALL ENTITY	
					RATE	ADDITIONAL FEE	RATE	ADDITIONAL FEE
Total	35	Minus	35	0	X \$ 25 =		X \$ 50 =	
Independent	3	Minus	3	0	X \$ 100 =		X \$ 200 =	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM								

RATE	ADDITIONAL FEE
X \$ 25 =	
X \$ 100 =	
+ \$ 180 =	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X \$ 50 =	
X \$ 200 =	
+ \$ 360 =	
TOTAL ADDIT. FEE	

AMENDMENT B	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	SMALL ENTITY		OTHER THAN SMALL ENTITY	
					RATE	ADDITIONAL FEE	RATE	ADDITIONAL FEE
Total	35	Minus	37	2	X \$ 25 =		X \$ 50 =	100
Independent	7	Minus	2	0	X \$ 100 =		X \$ 200 =	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM								

RATE	ADDITIONAL FEE
X \$ 25 =	
X \$ 100 =	
+ \$ 180 =	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X \$ 50 =	100
X \$ 200 =	
+ \$ 360 =	
TOTAL ADDIT. FEE	100

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than "20", enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than "3", enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

Rec'd PCT/PTO 13 FEB 2006

"Express Mail" Label No. EV 566969828 US
Date of Deposit February 13, 2006

PATENT

Attorney Docket No.: 082368-004800US
Client Ref. No.: E1-A0204P-US

10/539534

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: Aaron Hokamura

Aaron Hokamura

File only

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kazuaki UMEDA et al.

Application No.: 10/539,534

Int'l Application No.: PCT/JP03/16549

Int'l Filing Date: December 24, 2003

For: HIGHLY EFFICIENT GENE
TARGETING VECTORS AND
METHODS FOR GENE TARGETING
IN EPITHELIAL CELL LINES

Customer No.: 20350

Confirmation No.

Examiner:

Technology Center/Art Unit:

PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

Appl. No.
Amtd. dated February 13, 2006
Preliminary Amendment

PATENT

REMARKS/ARGUMENTS


Claims 1 through 24 are pending with entry of this amendment. Claims 7-9, 11, 12, 14, 18, 19 and 22 have been amended. Claims 23 and 24 have been added.

The amendments to claims 7-9, 11, 12, 14, 18, 19 and 22 merely correct improper multiple dependencies. Claims 23 and 24 have been added to maintain the scope of original claims 12 and 13. No new matter is added.

Applicants respectfully request entry of this amendment.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,


Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
KLB:ath
60518828 v1

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 082368-004800US
INTERNATIONAL APPLICATION NO. PCT/JP03/16549	INTERNATIONAL FILING DATE December 24, 2003	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/539,534
TITLE OF INVENTION HIGHLY EFFICIENT GENE TARGETING VECTORS AND METHODS FOR GENE TARGETING IN EPITHELIAL CELL LINES		PRIORITY DATE CLAIMED December 24, 2002
APPLICANT(S) FOR DO/EO/US Kazuaki UMEDA; Takeshi MATSUI; and Mayumi NAKAYAMA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). </p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the Inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 20 below concern document(s) or information included:		
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p>		
<p>14. <input type="checkbox"/> Data sheet(s) under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter.</p>		
<p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p>		

- a. A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. 20-1430 in the amount of \$ 1340.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 20-1430. A duplicate copy of this sheet is enclosed.
- d. Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Kevin Bastian
TOWNSEND AND TOWNSEND AND CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834



SIGNATURE

Kevin Bastian
NAME

34.774
REGISTRATION NUMBER

60701917 v1